Bank of New York Mellon’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-798,073
| Closed | -$8.94M | – | 4466 |
|
|
2017
Q3 | $8.94M | Sell |
798,073
-5,311
| -0.7% | -$58.6K | ﹤0.01% | 2042 |
|
|
2017
Q2 | $8.84M | Sell |
803,384
-23,655
| -3% | -$237K | ﹤0.01% | 2040 |
|
|
2017
Q1 | $8.11M | Buy |
827,039
+24,583
| +3% | +$246K | ﹤0.01% | 2077 |
|
|
2016
Q4 | $8.67M | Buy |
802,456
+60,991
| +8% | +$610K | ﹤0.01% | 2026 |
|
|
2016
Q3 | $7.6M | Buy |
741,465
+143,925
| +24% | +$1.57M | ﹤0.01% | 2005 |
|
|
2016
Q2 | $7.8M | Buy |
597,540
+313,888
| +111% | +$4.11M | ﹤0.01% | 1976 |
|
|
2016
Q1 | $3.12M | Sell |
283,652
-10,207
| -3% | -$90.8K | ﹤0.01% | 2414 |
|
|
2015
Q4 | $2.7M | Sell |
293,859
-15,215
| -5% | -$127K | ﹤0.01% | 2535 |
|
|
2015
Q3 | $2.15M | Sell |
309,074
-65,381
| -17% | -$560K | ﹤0.01% | 2696 |
|
|
2015
Q2 | $3.68M | Buy |
374,455
+36,970
| +11% | +$337K | ﹤0.01% | 2551 |
|
|
2015
Q1 | $2.99M | Buy |
337,485
+12,668
| +4% | +$101K | ﹤0.01% | 2606 |
|
|
2014
Q4 | $2.85M | Sell |
324,817
-683
| -0.2% | -$5.53K | ﹤0.01% | 2627 |
|
|
2014
Q3 | $2.24M | Sell |
325,500
-16,446
| -5% | -$98.6K | ﹤0.01% | 2790 |
|
|
2014
Q2 | $1.8M | Sell |
341,946
-6,292
| -2% | -$30.6K | ﹤0.01% | 2965 |
|
|
2014
Q1 | $1.58M | Sell |
348,238
-10,849
| -3% | -$52.4K | ﹤0.01% | 3034 |
|
|
2013
Q4 | $1.81M | Buy |
359,087
+1,136
| +0.3% | +$5.47K | ﹤0.01% | 2949 |
|
|
2013
Q3 | $1.81M | Sell |
357,951
-404
| -0.1% | -$2.25K | ﹤0.01% | 2902 |
|
|
2013
Q2 | $1.78M | Buy |
+358,355
| New | +$1.71M | ﹤0.01% | 2863 |
|
Bank of New York Mellon's SCLN Position: Q4 2017 in Review
Bank of New York Mellon sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 798,073 shares — an estimated $8.94M sold.
Bank of New York Mellon first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $8.94M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Bank of New York Mellon reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Bank of New York Mellon sold 798,073 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $8.94M.
- Bank of New York Mellon first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Bank of New York Mellon's Sciclone Pharmaceuticals Inc position peaked at $8.94M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Bank of New York Mellon's 13F filing for Q4 2017, filed 9 Feb 2018.